The association of multiple anti-hypertensive medication classes with Alzheimer's disease incidence across sex, race, and ethnicity.
Douglas BartholdGeoffrey JoyceWhitney WhartonPatrick KehoeJulie ZissimopoulosPublished in: PloS one (2018)
Hypertension management treatments that include RAS-acting ARBs may, in addition to lowering blood pressure, reduce AD risk, particularly for white and black women and white men. Additional studies and clinical trials that include men and women from different racial and ethnic groups are needed to confirm these findings. Understanding the potentially beneficial effects of certain RAS-acting AHTs in high-risk populations is of great importance.
Keyphrases
- blood pressure
- clinical trial
- hypertensive patients
- wild type
- heart rate
- polycystic ovary syndrome
- risk factors
- healthcare
- cognitive decline
- breast cancer risk
- blood glucose
- middle aged
- type diabetes
- adverse drug
- phase ii
- cervical cancer screening
- pregnant women
- emergency department
- genetic diversity
- metabolic syndrome
- adipose tissue
- open label
- study protocol
- randomized controlled trial
- skeletal muscle
- insulin resistance
- glycemic control
- drug induced